Literature DB >> 15740940

Inability to perform maximal stair climbing test before lung resection: a propensity score analysis on early outcome.

Alessandro Brunelli1, Armando Sabbatini, Francesco Xiume', Alessandro Borri, Michele Salati, Rita Daniela Marasco, Aroldo Fianchini.   

Abstract

OBJECTIVE: The objective of the present study was to assess whether patients unable to perform a preoperative maximal stair climbing test had an increased incidence of morbidity and mortality after major lung resection compared to patients who were able to exercise.
METHODS: Three hundred and ninety one patients submitted to pulmonary lobectomy or pneumonectomy for lung cancer were analyzed. Forty-five of these patients were unable to perform a preoperative maximal stair climbing test for underlying comorbidities. Unadjusted and propensity score case matched comparisons were performed between patients who could and who could not perform a preoperative stair climbing test. Multi-variable analyses were then performed to identify predictors of morbidity and mortality, and were validated by bootstrap bagging.
RESULTS: Patients who could not perform the stair climbing test had similar morbidity rates (31.1 vs. 35.6%, respectively, P=0.7), but higher mortality rates (15.6 vs. 4.4%, respectively, P=0.08) and deaths among complicated patients (50 vs. 12.5%, respectively, P=0.025), compared to propensity score matched patients who could perform the stair climbing test. Logistic regression analyses showed that the inability to perform the stair climbing test was an independent and reliable predictor of mortality (P=0.005) but not of morbidity (P=0.2).
CONCLUSIONS: Patients unable to perform a preoperative maximal exercise test had an increased risk of mortality after major lung resection. Half of these patients did not survive postoperative complications, due to their decreased aerobic reserve caused by physical inactivity which made them unable to cope with the increased oxygen demand.

Entities:  

Mesh:

Year:  2005        PMID: 15740940     DOI: 10.1016/j.ejcts.2004.11.012

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  6 in total

Review 1.  Risk assessment of lung resection for lung cancer according to pulmonary function: republication of systematic review and proposals by guideline committee of the Japanese association for chest surgery 2014.

Authors:  Noriyoshi Sawabata; Takashi Nagayasu; Yoshihisa Kadota; Taichiro Goto; Hiroyoshi Horio; Takeshi Mori; Shinichi Yamashita; Akinori Iwasaki
Journal:  Gen Thorac Cardiovasc Surg       Date:  2014-09-27

2.  The Walking Impairment Questionnaire stair-climbing score predicts mortality in men and women with peripheral arterial disease.

Authors:  Atul Jain; Kiang Liu; Luigi Ferrucci; Michael H Criqui; Lu Tian; Jack M Guralnik; Huimin Tao; Mary M McDermott
Journal:  J Vasc Surg       Date:  2012-06       Impact factor: 4.268

Review 3.  The Utility of Exercise Testing in Patients with Lung Cancer.

Authors:  Duc Ha; Peter J Mazzone; Andrew L Ries; Atul Malhotra; Mark Fuster
Journal:  J Thorac Oncol       Date:  2016-05-05       Impact factor: 15.609

4.  The effect of in-patient chest physiotherapy in lung cancer patients.

Authors:  Sevgi Ozalevli; Duygu Ilgin; Hayriye Kul Karaali; Serpil Bulac; Atilla Akkoclu
Journal:  Support Care Cancer       Date:  2009-05-28       Impact factor: 3.603

5.  Physiological Biomarkers Assessed by Low-Tech Exercise Tests Predict Complications and Overall Survival in Patients Undergoing Pneumonectomy Due to Lung Cancer.

Authors:  Tomasz Marjanski; Damian Wnuk; Robert Dziedzic; Marcin Ostrowski; Wioletta Sawicka; Ewa Marjanska; Witold Rzyman
Journal:  Cancers (Basel)       Date:  2021-02-10       Impact factor: 6.639

Review 6.  Functional capacity, physical activity and muscle strength assessment of individuals with non-small cell lung cancer: a systematic review of instruments and their measurement properties.

Authors:  Catherine L Granger; Christine F McDonald; Selina M Parry; Cristino C Oliveira; Linda Denehy
Journal:  BMC Cancer       Date:  2013-03-20       Impact factor: 4.430

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.